Nelson Dusetti: We are grateful to INCa for funding our project – NeoPREDICT

Nelson Dusetti shared a post on LinkedIn:  .

“We are grateful to INCa for funding our project NeoPREDICT: A multicentric phase II trial to personalize neoadjuvant chemotherapy for patients with borderline resectable pancreatic adenocarcinoma using the Pancreas View signature.”

Source: Nelson Dusetti/LinkedIn

Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.